Contact
searchSearch
HMP Global
Login

Advertisement

Advertisement

ADVERTISEMENT

Tardive Dyskinesia Excellence Forum

Tardive Dyskinesia
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Dr Chepke
Q&As
Vigilant Screening for Tardive Dyskinesia Among Recommendations to Mitigate Symptom Severity
06/22/2021
Clinicians should be vigilant about screening patients for TD as earlier detection is key in improving or slowing illness severity, suggests Craig Chepke, MD, FAPA in this Q&A that expands on his Elevate session.
Clinicians should be vigilant about screening patients for TD as earlier detection is key in improving or slowing illness severity, suggests Craig Chepke, MD, FAPA in this Q&A that expands on his Elevate session.
Clinicians should be vigilant...
06/22/2021
Psych Congress Network
Videos
Telephone Visits Not Recommended Telehealth Treatment Medium For TD Evaluation
06/07/2021
Rif El-Mallakh, MD, discusses his study that found that experts feel telephone visits are not adequate for the evaluation of TD and video interviews should be utilized instead to see the patient’s physical health.
Rif El-Mallakh, MD, discusses his study that found that experts feel telephone visits are not adequate for the evaluation of TD and video interviews should be utilized instead to see the patient’s physical health.
Rif El-Mallakh, MD, discusses...
06/07/2021
Psych Congress Network
Dr Rif El-Mallakh
Videos
Panel Study Investigates the Assessment and Treatment of Tardive Dyskinesia
06/03/2021
Rif El-Mallakh, MD, discusses the methods of his study that sought to learn more about how clinicians diagnose, assess, and manage TD in both in-person and telehealth settings and how TD impacts both patients and their caregivers.
Rif El-Mallakh, MD, discusses the methods of his study that sought to learn more about how clinicians diagnose, assess, and manage TD in both in-person and telehealth settings and how TD impacts both patients and their caregivers.
Rif El-Mallakh, MD, discusses...
06/03/2021
Psych Congress Network
Similarities and Differences Between TD Treatments
Videos
Similarities and Differences Between TD Treatments
04/26/2021
Psych Congress Steering Committee member Rakesh Jain, MD, MPH, explains the similarities and differences between the 2 medications approved by the US Food and Drug Administration for the treatment of tardive dyskinesia.
Psych Congress Steering Committee member Rakesh Jain, MD, MPH, explains the similarities and differences between the 2 medications approved by the US Food and Drug Administration for the treatment of tardive dyskinesia.
Psych Congress Steering...
04/26/2021
Psych Congress Network
Managing the Most Common Side Effects of VMAT2 Inhibitors
Videos
Managing the Most Common Side Effects of VMAT2 Inhibitors
04/22/2021
Psych Congress Steering Committee member Rakesh Jain, MD, MPH, answers the question "What are the most common side effects of VMAT2 inhibitors and how can clinicians help patients manage them?"
Psych Congress Steering Committee member Rakesh Jain, MD, MPH, answers the question "What are the most common side effects of VMAT2 inhibitors and how can clinicians help patients manage them?"
Psych Congress Steering...
04/22/2021
Psych Congress Network
Understanding the New TD Treatment Guidelines
Videos
Understanding the New TD Treatment Guidelines
04/22/2021
Psych Congress Steering Committee member Rakesh Jain, MD, MPH, discusses recent guidelines on identifying and treating tardive dyskinesia.
Psych Congress Steering Committee member Rakesh Jain, MD, MPH, discusses recent guidelines on identifying and treating tardive dyskinesia.
Psych Congress Steering...
04/22/2021
Psych Congress Network
Deutetrabenazine Effective for TD Across Age Groups
Videos
Deutetrabenazine Effective for TD Across Age Groups
10/05/2020
Martha Sajatovic, MD, provides details of a study which found that deutetrabenazine was effective as a treatment for tardive dyskinesia both in patients aged less than 55 years and in patients aged 55 years or older.
Martha Sajatovic, MD, provides details of a study which found that deutetrabenazine was effective as a treatment for tardive dyskinesia both in patients aged less than 55 years and in patients aged 55 years or older.
Martha Sajatovic, MD, provides...
10/05/2020
Psych Congress Network

Advertisement

Advertisement

Advertisement

Advertisement

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Advertisement

Advertisement

Sign Up

Psych Congress Network Newsletter

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use

Advertisement

Advertisement